SCHEMBL3538100

SCHEMBL3538100

Cc1cc(-c2nc(C(=O)N3CCCC4CCCC=C43)cs2)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
CLK1 P49759 1/20 0.38
KMT2A Q03164 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
EIF4E P06730 3/20 0.37
HTR2C P28335 4/20 0.37
ALDH1A1 P00352 5/20 0.36
ABL1 P00519 1/20 0.35
CHEK1 O14757 1/20 0.35
ACKR3 P25106 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4D Q08499 1/20 0.34
RAB9A P51151 3/20 0.34
HPGD P15428 3/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540045 0.94 KDM4E (0.39) KDM4ECLK1KMT2ARXFP1HCRTR1
SCHEMBL3538095 0.89 HTR2C (0.37) KDM4ECLK1KMT2ARXFP1HCRTR1
SCHEMBL3535269 0.87 UCHL1 (0.39) KDM4ECLK1KMT2ARXFP1EIF4E
SCHEMBL3542690 0.86 RAB9A (0.45) KDM4EKMT2AHTR2CALDH1A1RAB9A
SCHEMBL3539439 0.86 ALDH1A1 (0.48) KDM4ECLK1KMT2ARXFP1ALDH1A1
SCHEMBL3541008 0.85 TLR7 (0.45) KDM4EKMT2ARXFP1HCRTR1HCRTR2
SCHEMBL3541313 0.84 PROKR1 (0.38) HCRTR1HCRTR2HTR2C
SCHEMBL3536786 0.84 GFER (0.38) KMT2AHTR2CABL1PDE4BPDE4D
SCHEMBL3543877 0.84 HTR2C (0.40) EIF4EHTR2C
SCHEMBL3537642 0.83 ACKR3 (0.38) KDM4ECLK1KMT2ARXFP1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101370796-A Thiazoles as 11 beta-HSD1 inhibitors HOFFMANN LA ROCHE (CH) 2009-02-18 CN claimed
CN-101370796-B Thiazoles as 11 beta-HSD1 inhibitors HOFFMANN LA ROCHE 2012-10-10 CN disclosed
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 US disclosed
CN-101370796-A Thiazoles as 11 beta-HSD1 inhibitors HOFFMANN LA ROCHE (CH) 2009-02-18 CN disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GOT2, PC, CYP11B2 KDM4E 1513/4885CLK1 941/4885KMT2A 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.